中国药房2024，Vol.35Issue(14)：1776-1780,5.DOI:10.6039/j.issn.1001-0408.2024.14.18
富马酸二甲酯治疗多发性硬化疗效与安全性的Meta分析
Efficacy and safety of dimethyl fumarate in the treatment of multiple sclerosis:a meta-analysis
摘要
Abstract
OBJECTIVE To evaluate the efficacy and safety of dimethyl fumarate(DMF)in the treatment of multiple sclerosis(MS).METHODS Retrieved from CBM,Web of Science,PubMed,the Cochrane Library,Embase,CNKI,Wanfang Data,and VIP,randomized controlled trials(RCTs)about DMF(trial group)versus other drugs or placebo(control group)were collected.After data screening and extraction,quality evaluation,meta-analysis was conducted by using RevMan 5.3 software.RESULTS A total of 6 literature were included,involving 638 patients.Results of meta-analysis showed that the proportion of patients with lesion changes after treatment in the trial group was lower than control group[MD=-0.65,95%CI(-1.27,-0.02),P=0.04];there was no statistical significance in recurrence rate[RR=1.06,95%CI(0.52,2.17),P=0.88],the proportion of patients with new lesions after treatment[RR=1.05,95%CI(0.62,1.80),P=0.85],expanded disability status scale after treatment[MD=0.02,95%CI(-0.18,0.23),P=0.82],the incidence of adverse events[RR=1.33,95%CI(0.97,1.84),P=0.08]or severe adverse events[RR=0.95,95%CI(0.48,1.90),P=0.89]between 2 groups.Results of sensitivity analysis showed the study obtained unstable recurrence rate and the incidence of adverse events,while other results were robust.CONCLUSIONS DMF can control the lesion progression in MS patients to some extent and doesn't increase the incidence of adverse events and serious adverse events,but there is no significant advantage in reducing the recurrence rate and controlling the disability progression.关键词
富马酸二甲酯/多发性硬化/疾病修饰治疗/复发率/不良事件Key words
dimethyl fumarate/multiple sclerosis/disease modification treatment/recurrence rate/adverse event分类
医药卫生引用本文复制引用
李凤云,兰瑞,赵铎,刘福贵,陈良辰..富马酸二甲酯治疗多发性硬化疗效与安全性的Meta分析[J].中国药房,2024,35(14):1776-1780,5.基金项目
国家自然科学基金项目(No.81973618) （No.81973618）
河南省中医药科学研究专项课题(No.2019ZYBJ09) （No.2019ZYBJ09）
